Vanguard Information Technology ETF (VGT)
| Assets | $148.49B |
| Expense Ratio | 0.09% |
| PE Ratio | 34.70 |
| Shares Out | 1.23B |
| Dividend (ttm) | $0.43 |
| Dividend Yield | 0.36% |
| Ex-Dividend Date | Jun 24, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 12.66% |
| Volume | 2,368,960 |
| Open | 119.34 |
| Previous Close | 119.17 |
| Day's Range | 118.59 - 119.59 |
| 52-Week Low | 83.09 |
| 52-Week High | 126.00 |
| Beta | 1.35 |
| Holdings | 324 |
| Inception Date | Jan 26, 2004 |
About VGT
Fund Home PageThe Vanguard Information Technology ETF (VGT) is an exchange-traded fund that mostly invests in information technology equity. The fund tracks a market cap-weighted index of companies in the US information technology sector. VGT was launched on Jan 26, 2004 and is issued by Vanguard.
Top 10 Holdings
62.38% of assets| Name | Symbol | Weight |
|---|---|---|
| NVIDIA Corporation | NVDA | 17.16% |
| Apple Inc. | AAPL | 16.25% |
| Microsoft Corporation | MSFT | 10.96% |
| Broadcom Inc. | AVGO | 4.21% |
| Micron Technology, Inc. | MU | 3.82% |
| Advanced Micro Devices, Inc. | AMD | 3.18% |
| Cisco Systems, Inc. | CSCO | 1.91% |
| Applied Materials, Inc. | AMAT | 1.69% |
| Intel Corporation | INTC | 1.65% |
| Lam Research Corporation | LRCX | 1.54% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 24, 2026 | $0.1384 | Jun 26, 2026 |
| Mar 24, 2026 | $0.09298 | Mar 26, 2026 |
| Dec 17, 2025 | $0.09463 | Dec 19, 2025 |
| Sep 24, 2025 | $0.10733 | Sep 26, 2025 |
| Jun 26, 2025 | $0.08785 | Jun 30, 2025 |
| Mar 25, 2025 | $0.09118 | Mar 27, 2025 |
Performance
VGT had a total return of 32.65% in the past year, including dividends. Since the fund's inception, the average annual return has been 15.00%.
News
3 ‘Strong Buy’ Technology ETFs That Could Rally More Than 25%
Vanguard Information Technology ETF ($VGT), Technology Select Sector SPDR Fund ($XLK), and iShares Semiconductor ETF ($SOXX) are three technology exchange-traded funds (ETFs) that are rated Strong Buy...
Microsoft's Earnings Beat: A Ripple Effect Across ETF Landscape
Driven by strong growth in the Azure cloud and Copilot businesses, Microsoft (MSFT) delivered another standout quarterly earnings report, topping Wall Street expectations and reinforcing the company's...
Vanguard’s VGT or BlackRock’s ARTY: Which Tech ETF Is the Better AI Buy for 2026?
Technology ETFs are a popular way to invest in the AI boom. Using TipRanks’ ETF Comparison Tool, we compare the Vanguard Information Technology ETF ($VGT) with Blackrock’s ($BLK) iShares Future…
This 24% Dividend Gets Riskier As The Market Surges
The stunning thing about this year's stock-market rally is that much of it has come in just the last couple of months.
We have had an ‘overweight waiting' on the IT sector since 2022: CFRA Research senior VP
CFRA Research senior vice president and head of technology Angelo Zino explains why Nvidia, AMD, Microsoft and Meta remain top ‘strong buy' picks amid the ongoing AI-driven tech rally on ‘Making Money...
SaaS-pocalypse Reversal? AI Memory Chips Slide, Software Finds Strength
In a reversal from the SaaS-pocalypse, software is finding strength while AI memory names like Micron (MU) and SanDisk (SNDK) are selling off. Kevin Hincks explains how this all plays into the big pic...
Vanguard Announces Share Splits for Five Equity Index ETFs
VALLEY FORGE, Pa., March 24, 2026 /PRNewswire/ -- Vanguard today announced plans to execute forward share splits for five equity index ETFs.
What next for the Nasdaq 100 Index and QQQ, VGT, and VGT ETFs?
The Nasdaq 100 Index has slumped in the past few weeks, erasing some of the gains made earlier this year when it jumped to a record high of $26,156. It dropped to $23,765, its lowest level since Septe...
Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study of Abenacianine (VGT-309) for Tumor Visualization During Lung Cancer Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the initiation of VISUALIZE 2, a Phase 3...
Worldwide Exchange: ETF Flows Week of September 29
CNBC's Frank Holland speaks with Robert Doll, CEO & CIO at Crossmark Global Investments, about the action in ETFs this week.
The Best Tech ETFs to Buy
Tech ETFs can deliver superb tax efficiency and growth potential, but investors must be aware of high volatility, concentration risk and stretched valuations.
Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American Society of Cl...
Vergent Bioscience to Present Data on Abenacianine for Injection (VGT-309) at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) wi...
Tips for investing in tech now
Big tech has dominated the markets, but with tariffs and market uncertainty, what should investors do with the sector now? Ivana Delevska, Spear Invest Founder and CIO, joins Wealth to give some tips ...
Avoid the QQQ ETF, buy this Nasdaq 100 ETF alternative instead
The Invesco QQQ ETF has become one of the best-performing funds in the United States in the past few decades by tracking the Nasdaq 100 index. It has soared from about $40 during its inception and mov...
AI-themed ETFs plunge in wake of DeepSeek news
Prices of exchange-traded funds with outsize exposure to Nvidia plunged in the initial hours of trading on Monday in reaction to news that a Chinese startup has launched a powerful new artificial inte...
Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted ...
Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company's Phase 2, ...
VOO, VGT, DIA ETF stocks suffered a harsh reversal: I'm buying
American stocks dived on Friday as concerns that the US was moving into a hard landing continued. The Vanguard S&P 500 ETF (VOO) ETF slumped to $490 on Friday, down by over 5.69% from its highest leve...
Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that data published in The Annals of Thoracic Surgery reinf...
Tech: Big inflows with one exception
Nathan Geraci, The ETF Store President, joins CNBC's Bob Pisani on ETF Edge to discuss the big inflows into tech.
Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The ...
Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that new results from the Phase 2 clinical program evaluati...
Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience Initiates Phase 2 VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries.
Nvidia's Stock Slide Has Taken a Toll on Semiconductor ETFs
Nvidia (NVDA) shares tumbled almost 9% last week after U.S. government officials announced more stringent curbs on exports of advanced AI chips to China, dragging down many technology-centric exchange...
Apple's Rough Week Dragged Many of the Biggest ETFs Down With It
Apple (AAPL) shares had a rough week, tumbling almost 6% and dragging down a number of popular exchange-traded funds (ETFs) that are heavily exposed to the world's most valuable company.
Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer.